IL91454A - Use of a human rhinovirus receptor preparation for the manufacture of medicaments for the treatment of rhinovirus infections - Google Patents

Use of a human rhinovirus receptor preparation for the manufacture of medicaments for the treatment of rhinovirus infections

Info

Publication number
IL91454A
IL91454A IL9145489A IL9145489A IL91454A IL 91454 A IL91454 A IL 91454A IL 9145489 A IL9145489 A IL 9145489A IL 9145489 A IL9145489 A IL 9145489A IL 91454 A IL91454 A IL 91454A
Authority
IL
Israel
Prior art keywords
receptor
hrv
rhinovirus
icam
protein
Prior art date
Application number
IL9145489A
Other languages
English (en)
Other versions
IL91454A0 (en
Original Assignee
Molecular Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Therapeutics Inc filed Critical Molecular Therapeutics Inc
Publication of IL91454A0 publication Critical patent/IL91454A0/xx
Publication of IL91454A publication Critical patent/IL91454A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Detergent Compositions (AREA)
IL9145489A 1988-09-01 1989-08-28 Use of a human rhinovirus receptor preparation for the manufacture of medicaments for the treatment of rhinovirus infections IL91454A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23957188A 1988-09-01 1988-09-01
US26242888A 1988-10-25 1988-10-25
US39066289A 1989-08-10 1989-08-10

Publications (2)

Publication Number Publication Date
IL91454A0 IL91454A0 (en) 1990-04-29
IL91454A true IL91454A (en) 1995-08-31

Family

ID=27399251

Family Applications (1)

Application Number Title Priority Date Filing Date
IL9145489A IL91454A (en) 1988-09-01 1989-08-28 Use of a human rhinovirus receptor preparation for the manufacture of medicaments for the treatment of rhinovirus infections

Country Status (15)

Country Link
US (1) US7132395B1 (fr)
EP (1) EP0362531B1 (fr)
JP (1) JP3253064B2 (fr)
AT (1) ATE186552T1 (fr)
AU (1) AU637324B2 (fr)
CA (1) CA1339193C (fr)
DE (1) DE68929096T2 (fr)
DK (1) DK174095B1 (fr)
ES (1) ES2141076T3 (fr)
FI (1) FI894065A7 (fr)
GR (1) GR3032456T3 (fr)
IL (1) IL91454A (fr)
NO (1) NO893373L (fr)
NZ (1) NZ230474A (fr)
PT (1) PT91570B (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6051231A (en) * 1988-09-01 2000-04-18 Bayer Corporation Antiviral methods and prepations
US6096862A (en) * 1990-07-20 2000-08-01 Bayer Corporation Multimeric antiviral agent
US6107461A (en) * 1990-07-20 2000-08-22 Bayer Corporation Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use
US6130202A (en) * 1990-07-20 2000-10-10 Bayer Corporation Antiviral methods
US6143298A (en) * 1988-09-01 2000-11-07 Bayer Corporation Soluble truncated forms of ICAM-1
US6326004B1 (en) 1988-09-01 2001-12-04 Bayer Corporation Antiviral methods using fragments of human rhinovirus receptor (ICAM-1)
US7132395B1 (en) 1988-09-01 2006-11-07 Bayer Pharmaceuticals Corporation Antiviral methods using human rhinovirus receptor (ICAM-1)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0303692A4 (en) * 1987-02-26 1990-12-05 Dana Farber Cancer Institute Cloning of lfa-1
US5151267A (en) * 1988-07-15 1992-09-29 University Of Saskatchewan Bovine herpesvirus type 1 polypeptides and vaccines
US5585264A (en) * 1988-07-15 1996-12-17 University Of Saskatchewan Nucleotide sequences encoding recombinant bovine herpesvirus type-1 GI, GIII and GIV polypeptides
ZA896668B (en) * 1988-09-01 1990-06-27 Molecular Therapeutics Inc A human rhinovirus receptor protein that inhibits virus infectivity
NO900155L (no) * 1989-01-24 1990-07-25 Molecular Therapeutics Inc Et opploeselig molekyl som er relatert til, men forskjellig fra icam-1.
JPH04505009A (ja) * 1989-03-09 1992-09-03 ダナ・ファーバー・キャンサー・インスティチュート クローニングｌｆａ―１
ATE219838T1 (de) * 1989-03-16 2002-07-15 Blood Res Center Verwendung von funktionellen derivaten des interzellulär-adhäsions-moleküls icam-1 in einer antivirus-therapie
WO1991018010A1 (fr) * 1990-05-15 1991-11-28 Swinburne Limited Inhibition d'infection virale a l'aide de peptides analogues a la molecule-1 d'adhesion intercellulaire et/ou d'analogues de ces peptides
US5686581A (en) * 1990-07-20 1997-11-11 Bayer Corporation Multimeric form of human rhinovirus receptor protein
US5686582A (en) * 1990-07-20 1997-11-11 Bayer Corporation Multimeric forms of human rhinovirus receptor protein
US5288854A (en) * 1990-11-28 1994-02-22 Center For Blood Research, Inc. Functional derivatives of ICAM-1 which are substantially capable of binding to LFA-1 but are substantially incapable of binding to MAC-1
US5629162A (en) * 1991-06-11 1997-05-13 The Center For Blood Research Method of identifying agents which modulate ICAM-3 binding to LFA-1
US5525487A (en) * 1992-01-27 1996-06-11 Icos Corporation DNA encoding I-CAM related protein
US6153395A (en) * 1992-01-27 2000-11-28 Icos Corporation ICAM-related protein
US5811517A (en) * 1992-01-27 1998-09-22 Icos Corporation ICAM-related protein variants
US6818743B1 (en) 1992-01-27 2004-11-16 Icos Corporation I-CAM related protein
US5989843A (en) * 1992-01-27 1999-11-23 Icos Corporation Methods for identifying modulators of protein kinase C phosphorylation of ICAM-related protein
US5532127A (en) * 1992-01-27 1996-07-02 Icos Corporation Assay for 1-CAM related protein expression
WO1993014776A1 (fr) * 1992-01-27 1993-08-05 Icos Corporation Proteine apparentee a icam
US5837822A (en) * 1992-01-27 1998-11-17 Icos Corporation Humanized antibodies specific for ICAM related protein
US6100383A (en) * 1992-01-27 2000-08-08 Icos Corporation Fusion proteins comprising ICAM-R polypeptides and immunoglobulin constant regions
AU710965B2 (en) * 1992-06-22 1999-09-30 Bayer Corporation Multimeric forms of human rhinovirus receptor protein
WO1994011400A1 (fr) * 1992-11-18 1994-05-26 Helsinki University Licensing Ltd. Oy Peptides de icam-2 et icam-1 chez l'homme et leurs analogues s'utilisant en therapie et diagnostic
GB9414966D0 (en) * 1994-07-26 1994-09-14 Danbiosyst Uk Pharmaceutical compositions for the nasal administration of antiviral agents
US5879712A (en) 1995-06-07 1999-03-09 Sri International Method for producing drug-loaded microparticles and an ICAM-1 dosage form so produced
DE69722594T2 (de) * 1996-03-06 2004-04-29 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Pulverförmiges arzneimittel enthaltend interzelluläres adhäsionsmolekül
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
CA2544678C (fr) 2003-11-05 2013-12-31 Sunesis Pharmaceuticals, Inc. Modulateurs de l'adhesion cellulaire
DK2444079T3 (en) 2005-05-17 2017-01-30 Sarcode Bioscience Inc Compositions and Methods for the Treatment of Eye Diseases
ES2830024T3 (es) 2007-10-19 2021-06-02 Novartis Ag Composiciones y métodos para el tratamiento del edema macular
WO2009139817A2 (fr) 2008-04-15 2009-11-19 Sarcode Corporation Produit pharmaceutique cristallin et ses procédés de préparation et d'utilisation
WO2011050175A1 (fr) 2009-10-21 2011-04-28 Sarcode Corporation Agent pharmaceutique cristallin et procédés de préparation et utilisation de celui-ci
KR20200108932A (ko) 2012-07-25 2020-09-21 에스에이알코드 바이오사이언스 인코포레이티드 Lfa-1 저해제 및 그의 다형체
EP3419629A4 (fr) 2016-02-25 2019-10-30 Applied Biological Laboratories, Inc. Compositions et procédés de protection contre des agents pathogènes et des substances irritantes aériens
US12447166B2 (en) 2016-02-25 2025-10-21 Applied Biological Laboratories, Inc. Compositions and methods for protecting against airborne pathogens and irritants

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4171365A (en) 1977-08-05 1979-10-16 Sterling Drug Inc. Antiviral aryloxyalkylpyrazoles
US4209526A (en) 1977-08-05 1980-06-24 Sterling Drug Inc. Antiviral arylenedioxyalkyl substituted pyrazoles
US4261928A (en) 1977-08-05 1981-04-14 Sterling Drug Inc. 2-Benzoyl-8-(2-chloro-4-methoxyphenoxy)-1-phenyl-1-octanone
FR2432170A1 (fr) 1978-06-12 1980-02-22 Corning Glass Works Procede de mesure de recepteurs d'antigene sur des membranes de cellules
US4234725A (en) 1979-10-24 1980-11-18 Sterling Drug Inc. 4-[6-(2-Chloro-4-methoxyphenoxy)hexyl]-3,5-diethyl-1-[4-(4-morpholinyl)-1-oxobutyl]-1H-pyrazole
US4232161A (en) 1979-10-24 1980-11-04 Sterling Drug Inc. 4-[6-(2-Chloro-4-methoxyphenoxy)hexyl]-3,5-diethyl-1-(2-pyridinyl)-1H-pyrazole
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4427653A (en) 1981-01-26 1984-01-24 President And Fellows Of Harvard College Method of making monoclonal antibodies
US4372976A (en) 1981-08-07 1983-02-08 Sterling Drug Inc. Novel aryl-aliphatic ketone and its use as an antiviral agent
US4451476A (en) 1982-12-13 1984-05-29 Sterling Drug Inc. Isoxazoles as antiviral agents
US4843087A (en) 1983-08-29 1989-06-27 Sterling Drug Inc. Di-heterocyclic compounds and their use as antiviral agents
EP0169146A3 (fr) * 1984-07-20 1988-07-20 Merck & Co. Inc. Anticoprs monoclonaux dirigés contre le récepteur cellulaire du rhinovirus humain
JPS6181798A (ja) 1984-07-23 1986-04-25 ベクトン・デイツキンソン・アンド・カンパニ− 細胞リセプタ−の回収
DE3505148A1 (de) 1985-02-15 1986-10-30 Boehringer Ingelheim International GmbH, 6507 Ingelheim Polypeptide des rhinovirusstammes hrv2 sowie die hierfuer codierenden dna-molekuele
CA1280753C (fr) 1985-07-02 1991-02-26 Philip Michael Carabateas Methode de preparation de derives de substitution heterocycliques de phenoxyalkylisoxasoles et de phenoxyalkylfuranes
EP0227604A3 (fr) 1985-12-23 1989-01-18 Sandoz Ag Emploi d'oligopeptides dans le traitement d'infections virales
EP0261403A3 (fr) 1986-08-23 1988-04-13 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Polypeptide de rhinovirus souche HRV89, et molécule d'ADN qui l'encode
DE3886237T2 (de) 1987-02-26 1994-05-05 Dana Farber Cancer Inst Inc Reinigung von LFA-3.
EP0303692A4 (en) 1987-02-26 1990-12-05 Dana Farber Cancer Institute Cloning of lfa-1
US5304636A (en) 1987-04-14 1994-04-19 Boehringer Ingelheim International Gmbh Receptor for the human rhinovirus minor group
DE3712678A1 (de) 1987-04-14 1988-10-27 Boehringer Ingelheim Int Rezeptor der kleinen rhinovirus rezeptor gruppe
US5603932A (en) 1987-04-14 1997-02-18 Boehringer Ingelheim International Gmbh Receptor of the minor human rhinovirus receptor group
US5831036A (en) 1987-05-04 1998-11-03 Dana Farber Cancer Institute Soluble fragments of human intercellular adhesion molecule-1
US5284931A (en) 1987-05-04 1994-02-08 Dana Farber Cancer Institute Intercellular adhesion molecules, and their binding ligands
AU629189B2 (en) 1987-05-04 1992-10-01 Dana-Farber Cancer Institute Intercellular adhesion molecules and their binding ligands
ES2080044T3 (es) * 1987-05-04 1996-02-01 Dana Farber Cancer Inst Inc Moleculas de adhesion intercelular y sus ligandos de fijacion.
US4956281A (en) 1987-06-03 1990-09-11 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3
US5109123A (en) 1988-06-14 1992-04-28 Dana Farber Cancer Institute Alteration of ability of soluble CD4 fragments to bind HIV
DE3852374T2 (de) 1987-11-02 1995-05-04 Baylor College Medicine Verwendung von ICAM-1 oder ihre funktionelle Derivate zur Behandlung unspezifischer Entzündungen.
US5081228A (en) 1988-02-25 1992-01-14 Immunex Corporation Interleukin-1 receptors
CA1341055C (fr) * 1987-12-08 2000-07-18 Alan Mcclelland Lignees cellulaires transfectantes exprimant le recepteur majeur du rhinovirus chez l'homme
US5395929A (en) 1987-12-15 1995-03-07 Dana Farber Cancer Institute Isolated nucleic acid encoding the alpha subunit of the human leukocyte adhesion receptor
EP0372056A4 (en) 1988-05-04 1991-05-15 Dana Farber Cancer Institute Protein micelles
DE68923048T2 (de) 1988-08-23 1995-11-16 Dana Farber Cancer Inst Inc Alpha-Subeinheit des LFA-1-Leukocyt-Adhäsions-Rezeptors.
US6514936B1 (en) * 1988-09-01 2003-02-04 Bayer Corporation Antiviral methods using human rhinovirus receptor (ICAM-1)
US6143298A (en) 1988-09-01 2000-11-07 Bayer Corporation Soluble truncated forms of ICAM-1
ZA896668B (en) 1988-09-01 1990-06-27 Molecular Therapeutics Inc A human rhinovirus receptor protein that inhibits virus infectivity
US6051231A (en) 1988-09-01 2000-04-18 Bayer Corporation Antiviral methods and prepations
ES2141076T3 (es) 1988-09-01 2000-03-16 Bayer Ag Proteina del receptor de rinovirus humano que inhibe la infectividad del virus.
ES2201052T3 (es) 1988-09-28 2004-03-16 Dana Farber Cancer Institute Moleculas de adhesion intercelular y sus ligandos de union.
AU4412889A (en) 1988-09-28 1990-04-18 Dana-Farber Cancer Institute Intercellular adhesion molecules, and their binding ligands
US5372933A (en) 1988-10-03 1994-12-13 The Scripps Research Institute Polypeptides that mimic receptor-induced binding sites, and methods of using same
US5235049A (en) 1989-01-24 1993-08-10 Molecular Therapeutics, Inc. Nucleic acid sequences encoding a soluble molecule (SICAM-1) related to but distinct from ICAM-1
NO900155L (no) 1989-01-24 1990-07-25 Molecular Therapeutics Inc Et opploeselig molekyl som er relatert til, men forskjellig fra icam-1.
PT92900A (pt) 1989-01-24 1990-07-31 Sistema de vectores de expressao para a producao de anticorpos monoclonais quimericos
CA2008368C (fr) 1989-01-24 2003-04-08 Jeffrey Greve Molecule soluble apparentee a l'icam-i mais distincte
ZA901842B (en) 1989-03-09 1990-12-28 Boehringer Ingelheim Pharma Use of intercellular adhesion molecules,and their binding ligans in the treatment of asthma
JPH04505009A (ja) 1989-03-09 1992-09-03 ダナ・ファーバー・キャンサー・インスティチュート クローニングｌｆａ―１
ES2035668T3 (es) 1989-03-09 1993-04-16 Boehringer Ingelheim Pharmaceuticals Inc. Uso de moleculas de adherencia intercelular y sus ligandos de union en el tratamiento del asma.
HU217792B (hu) 1989-03-16 2000-04-28 Dana Farber Cancer Institute Eljárás intercelluláris adhéziós molekula (ICAM-1) oldható származékai és ezeket tartalmazó gyógyszerkészítmények előállítására
ATE219838T1 (de) 1989-03-16 2002-07-15 Blood Res Center Verwendung von funktionellen derivaten des interzellulär-adhäsions-moleküls icam-1 in einer antivirus-therapie
ZA903223B (en) 1989-04-28 1991-02-27 Baylor College Medicine Dissemination of hiv-1 infected cells
US5324510A (en) 1989-09-01 1994-06-28 Boehringer Ingelheim Pharmaceuticals, Inc. Use of antibodies to intercellular adhesion molecule-1 (ICAM-1) in the treatment of asthma
GB9009549D0 (en) 1990-04-27 1990-06-20 Celltech Ltd Recombinant antibody and method
GB9009548D0 (en) 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
WO1991018010A1 (fr) 1990-05-15 1991-11-28 Swinburne Limited Inhibition d'infection virale a l'aide de peptides analogues a la molecule-1 d'adhesion intercellulaire et/ou d'analogues de ces peptides
WO1991018011A1 (fr) 1990-05-15 1991-11-28 Swinburne Limited Inhibition d'adhesion cellulaire a l'aide de peptides analogues a la molecule-1-d'adhesion intercellulaire et/ou d'analogues de ces peptides
EP0459577A3 (en) 1990-06-01 1992-08-05 Merck & Co. Inc. Microbially expressed portions of a monoclonal antibody block rhinovirus attachment to cell receptors
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
JPH06504186A (ja) 1990-07-13 1994-05-19 ザ ジェネラル ホスピタル コーポレイション Ｃｄ５３細胞表面抗原とその使用
US5686581A (en) 1990-07-20 1997-11-11 Bayer Corporation Multimeric form of human rhinovirus receptor protein
US5686582A (en) 1990-07-20 1997-11-11 Bayer Corporation Multimeric forms of human rhinovirus receptor protein
US6130202A (en) * 1990-07-20 2000-10-10 Bayer Corporation Antiviral methods
US6107461A (en) 1990-07-20 2000-08-22 Bayer Corporation Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use
ES2134762T3 (es) 1990-07-20 1999-10-16 Bayer Ag Formas multimericas de proteinas receptoras de rinovirus humanos.
WO1992003473A1 (fr) 1990-08-27 1992-03-05 Cetus Corporation Medicaments peptidiques a base de cd18 utilises dans le traitement d'affections
WO1992006119A1 (fr) 1990-10-03 1992-04-16 Boehringer Ingelheim Pharmaceuticals, Inc. Procede de traitement de l'inflammation en utilisant des anticorps anti-idiotypiques
US5288854A (en) 1990-11-28 1994-02-22 Center For Blood Research, Inc. Functional derivatives of ICAM-1 which are substantially capable of binding to LFA-1 but are substantially incapable of binding to MAC-1
WO1992010591A1 (fr) 1990-12-14 1992-06-25 Cell Genesys, Inc. Chaines chimeriques utilisees comme voies de transduction de signal associe a un recepteur
US5709859A (en) 1991-01-24 1998-01-20 Bristol-Myers Squibb Company Mixed specificity fusion proteins
EP0510483A1 (fr) 1991-04-22 1992-10-28 Boehringer Ingelheim Pharmaceuticals Inc. Procédé pour la détection des virus
US5223396A (en) 1991-05-03 1993-06-29 Boehringer Ingelheim Pharmaceuticals, Inc. Method for detecting organ transplant rejection
US5240694A (en) 1991-09-23 1993-08-31 University Of Virginia Combined antiviral and antimediator treatment of common colds
WO1993006842A1 (fr) 1991-10-02 1993-04-15 Boehringer Ingelheim Pharmaceuticals, Inc. Utilisation de molecules d'adhesion intercellulaire et de leurs ligands de liaison dans le traitement de l'asthme
AU2797892A (en) 1991-10-03 1993-05-03 Center For Blood Research, The (plasmodium falciparum)-infected erythrocytes binding to icam-1 and cd36
DE69229275T2 (de) 1991-10-04 1999-12-30 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Rockville Herstellung eines arzneimittels zur behandlung von augenentzündung durch blockierung von zelladhäsionsmolekulen
US5861151A (en) 1991-12-20 1999-01-19 Bristol-Myers Squibb Co Soluble fusion molecules with binding specificity for cell adhesion molecules
US5525487A (en) 1992-01-27 1996-06-11 Icos Corporation DNA encoding I-CAM related protein
US5532127A (en) 1992-01-27 1996-07-02 Icos Corporation Assay for 1-CAM related protein expression
WO1993014776A1 (fr) 1992-01-27 1993-08-05 Icos Corporation Proteine apparentee a icam
DK0566554T3 (da) 1992-03-13 2000-08-07 Monsanto Co Fremstilling af rekombinante proteiner ved anvendelse af herpesviruspromotorer og VP16-transaktivatorer
JPH06510208A (ja) 1992-06-22 1994-11-17 マイルス・インコーポレーテツド 多量体形態のヒトライノウイルスレセプタ蛋白質
JPH06510673A (ja) 1992-07-08 1994-12-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ヒトライノウイルスに対する結合部位を有する受容体誘導体
US5580969A (en) 1992-07-24 1996-12-03 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ICAM-I RNA
WO1994011400A1 (fr) 1992-11-18 1994-05-26 Helsinki University Licensing Ltd. Oy Peptides de icam-2 et icam-1 chez l'homme et leurs analogues s'utilisant en therapie et diagnostic
EP0757697A4 (fr) 1994-04-12 2000-05-17 Boehringer Ingelheim Pharma Utilisation d'agents bloquant l'interaction molecule d'adhesion intercellulaire/recepteur dans le traitement d'une infection respiratoire virale
WO1995028170A1 (fr) 1994-04-19 1995-10-26 The University Of Kansas Peptides a chaine courte a base d'icam-1/lfa-1 et leur methode d'utilisation
GB9414966D0 (en) 1994-07-26 1994-09-14 Danbiosyst Uk Pharmaceutical compositions for the nasal administration of antiviral agents
AU3159595A (en) 1994-08-30 1996-03-22 Hyal Pharmaceutical Corporation Hyaluronic acid and derivatives for modulation of cellular activity
US5733540A (en) 1995-03-08 1998-03-31 Lee; Peter Poon-Hang Protection from viral infection via colonization of mucosal membranes with genetically modified bacteria
US5695760A (en) 1995-04-24 1997-12-09 Boehringer Inglehiem Pharmaceuticals, Inc. Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation
US5879712A (en) 1995-06-07 1999-03-09 Sri International Method for producing drug-loaded microparticles and an ICAM-1 dosage form so produced
ES2222775B1 (es) 2002-01-31 2006-12-16 Laboratorios Indas, S.A. Procedimiento para la deteccion de una predisposicion a una enfermedad cardiovascular.
AUPS161102A0 (en) 2002-04-08 2002-05-16 Industrial Engineering Technology Pty Ltd Improved gas burner

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6051231A (en) * 1988-09-01 2000-04-18 Bayer Corporation Antiviral methods and prepations
US6143298A (en) * 1988-09-01 2000-11-07 Bayer Corporation Soluble truncated forms of ICAM-1
US6326004B1 (en) 1988-09-01 2001-12-04 Bayer Corporation Antiviral methods using fragments of human rhinovirus receptor (ICAM-1)
US6514936B1 (en) 1988-09-01 2003-02-04 Bayer Corporation Antiviral methods using human rhinovirus receptor (ICAM-1)
US7132395B1 (en) 1988-09-01 2006-11-07 Bayer Pharmaceuticals Corporation Antiviral methods using human rhinovirus receptor (ICAM-1)
US6096862A (en) * 1990-07-20 2000-08-01 Bayer Corporation Multimeric antiviral agent
US6107461A (en) * 1990-07-20 2000-08-22 Bayer Corporation Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use
US6130202A (en) * 1990-07-20 2000-10-10 Bayer Corporation Antiviral methods

Also Published As

Publication number Publication date
FI894065A0 (fi) 1989-08-30
JP3253064B2 (ja) 2002-02-04
NO893373L (no) 1990-03-02
JPH02238892A (ja) 1990-09-21
PT91570B (pt) 1995-05-31
NO893373D0 (no) 1989-08-22
FI894065L (fi) 1990-03-02
AU4027189A (en) 1990-03-08
AU637324B2 (en) 1993-05-27
DK431289D0 (da) 1989-08-31
EP0362531B1 (fr) 1999-11-10
US7132395B1 (en) 2006-11-07
PT91570A (pt) 1990-03-30
GR3032456T3 (en) 2000-05-31
ES2141076T3 (es) 2000-03-16
DE68929096D1 (de) 1999-12-16
EP0362531A1 (fr) 1990-04-11
DE68929096T2 (de) 2000-05-11
ATE186552T1 (de) 1999-11-15
NZ230474A (en) 1993-03-26
DK174095B1 (da) 2002-06-10
DK431289A (da) 1990-03-02
FI894065A7 (fi) 1990-03-02
IL91454A0 (en) 1990-04-29
CA1339193C (fr) 1997-08-05

Similar Documents

Publication Publication Date Title
US7132395B1 (en) Antiviral methods using human rhinovirus receptor (ICAM-1)
US5589453A (en) Human rhinovirus receptor protein (ICAM-1) that inhibits rhinovirus attachment and infectivity
JP2997053B2 (ja) ヒトリンパ球により生成されるタンパク質、それらのタンパク質をコードするｄｎａ配列及びそれらの医薬及び生物学的使用
FI106316B (fi) Ihmisen C3b/C4b-reseptori (CR1)
KR0178024B1 (ko) 세포간 점착 분자 icam-1의 가용성 단편을 포함하는 항-바이러스제 및 이를 사용한 진단 방법
EP0468257B1 (fr) Formes multimériques du récepteur du rhinovirus humain
JP2003159088A (ja) 組換えトロンビンレセプターおよびそれに関連した薬剤
IE84069B1 (en) Recombinant thrombin receptor and related pharmaceuticals
JP2003089654A (ja) リンパ球機能関連抗原３のｃｄ２結合ドメイン
US6051231A (en) Antiviral methods and prepations
US5674982A (en) Multimeric form of human rhinovirus receptor protein
US6326004B1 (en) Antiviral methods using fragments of human rhinovirus receptor (ICAM-1)
Lineberger et al. Antibodies that block rhinovirus attachment map to domain 1 of the major group receptor
EP0414178A2 (fr) Polypeptides CD4 de primates non humains et molécules CD4 humaines susceptibles d'être glycosylées
US5686582A (en) Multimeric forms of human rhinovirus receptor protein
JPH07502495A (ja) 特定種のｌｆａ−３またはｃｄ２結合蛋白質を投与することによる同種移植または異種移植の寛容性を改善するための方法
US6066321A (en) Method for antagonizing vascular adhesion protein-1 (VAP-1)-mediated binding of endothelial cells to lymphocytes
EP1757614A1 (fr) Diagnostic et traitement des affections liées à la surcharge en fer et des affections ferriprives, procédés et compositions appropriés
Düchler et al. NKG2‐C is a receptor on human natural killer cells that recognizes structures on K562 target cells
Richardson et al. Adhesion domain of human T11 (CD2) is encoded by a single exon.
US6143298A (en) Soluble truncated forms of ICAM-1
US6797270B1 (en) Functional derivatives of the intercellular adhesion molecule ICAM-1 in anti-viral therapy
US6107461A (en) Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use
JPH09512426A (ja) 好中球の接着および移動の遮断に有用なＭａｃ−１ Ｉ−ドメイン蛋白質
Benyhe et al. [3H] Dynorphin1–8 binding sites in frog (Rana esculenta) brain membranes

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired